Lexaria Bioscience Corp. reports developments in drug-delivery research centered on DehydraTECH, its patented formulation and processing platform for oral delivery of pharmaceutical compounds. Company news commonly covers GLP-1 programs involving semaglutide and liraglutide, human pilot study results, research plans, and formulation work aimed at oral alternatives to injectable therapies.
Recurring updates also include patent grants across DehydraTECH applications, commentary on the oral GLP-1 market, business-development discussions with pharmaceutical companies, and shareholder-meeting communications. The company operates a licensed in-house research laboratory and uses its intellectual property portfolio as a central part of its drug-delivery platform strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.